BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 30854504)

  • 1. Genomic Characterization of Upper-Tract Urothelial Carcinoma in Patients With Lynch Syndrome.
    Donahue TF; Bagrodia A; Audenet F; Donoghue MTA; Cha EK; Sfakianos JP; Sperling D; Al-Ahmadie H; Clendenning M; Rosty C; Buchanan DD; Jenkins M; Hopper J; Winship I; Templeton AS; Walsh MF; Stadler ZK; Iyer G; Taylor B; Coleman J; Lindor NM; Solit DB; Bochner BH
    JCO Precis Oncol; 2018; 2018():. PubMed ID: 30854504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic Characterization of Upper Tract Urothelial Carcinoma.
    Sfakianos JP; Cha EK; Iyer G; Scott SN; Zabor EC; Shah RH; Ren Q; Bagrodia A; Kim PH; Hakimi AA; Ostrovnaya I; Ramirez R; Hanrahan AJ; Desai NB; Sun A; Pinciroli P; Rosenberg JE; Dalbagni G; Schultz N; Bajorin DF; Reuter VE; Berger MF; Bochner BH; Al-Ahmadie HA; Solit DB; Coleman JA
    Eur Urol; 2015 Dec; 68(6):970-7. PubMed ID: 26278805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy.
    Tang Q; Zuo W; Wan C; Xiong S; Xu C; Yuan C; Sun Q; Zhou L; Li X
    Front Immunol; 2022; 13():1097730. PubMed ID: 36818471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Germline Mutations in Upper Tract Urothelial Carcinoma With Suspected Lynch Syndrome.
    Guan B; Wang J; Li X; Lin L; Fang D; Kong W; Tian C; Li J; Yang K; Han G; Wu Y; He Y; Peng Y; Yu Y; He Q; He S; Gong Y; Zhou L; Tang Q
    Front Oncol; 2022; 12():774202. PubMed ID: 35372080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma.
    Audenet F; Isharwal S; Cha EK; Donoghue MTA; Drill EN; Ostrovnaya I; Pietzak EJ; Sfakianos JP; Bagrodia A; Murugan P; Dalbagni G; Donahue TF; Rosenberg JE; Bajorin DF; Arcila ME; Hechtman JF; Berger MF; Taylor BS; Al-Ahmadie H; Iyer G; Bochner BH; Coleman JA; Solit DB
    Clin Cancer Res; 2019 Feb; 25(3):967-976. PubMed ID: 30352907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upper Tract Urothelial Carcinoma in the Lynch Syndrome Tumour Spectrum: A Comprehensive Overview from the European Association of Urology - Young Academic Urologists and the Global Society of Rare Genitourinary Tumors.
    Lonati C; Necchi A; Gómez Rivas J; Afferi L; Laukhtina E; Martini A; Ventimiglia E; Colombo R; Gandaglia G; Salonia A; Briganti A; Montorsi F; Mattei A; Simeone C; Carlo MI; Shariat SF; Spiess PE; Moschini M;
    Eur Urol Oncol; 2022 Feb; 5(1):30-41. PubMed ID: 34896051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological Features of FGFR3 - Mutated Upper Tract Urothelial Carcinoma: A Genomic Database Analysis.
    Rizzo A; Mollica V; Santoni M; Massari F
    Clin Genitourin Cancer; 2022 Oct; 20(5):482-487. PubMed ID: 35858936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.
    Necchi A; Madison R; Pal SK; Ross JS; Agarwal N; Sonpavde G; Joshi M; Yin M; Miller VA; Grivas P; Chung JH; Ali SM
    Eur Urol Focus; 2021 Nov; 7(6):1339-1346. PubMed ID: 32861617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular intricacies of upper tract urothelial carcinoma and their relevance for therapy considerations.
    Berndl F; Hassler MR
    Curr Opin Urol; 2022 Jan; 32(1):48-53. PubMed ID: 34772864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Genomic Characterization in Upper Tract Urothelial Carcinoma and Urothelial Carcinoma of the Bladder.
    Yang K; Yu W; Liu H; Ding F; Zhang Y; Zhang Y; Wang W; Lou F; Cao S; Wang H; He Z
    Oncologist; 2021 Aug; 26(8):e1395-e1405. PubMed ID: 34050578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lynch syndrome and exposure to aristolochic acid in upper-tract urothelial carcinoma: its clinical impact?
    Colin P; Seisen T; Mathieu R; Shariat SF; Rouprêt M
    Transl Androl Urol; 2016 Oct; 5(5):648-654. PubMed ID: 27785421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genitourinary manifestations of Lynch syndrome in the urological practice.
    Lonati C; Simeone C; Suardi N; Spiess PE; Necchi A; Moschini M
    Asian J Urol; 2022 Oct; 9(4):443-450. PubMed ID: 36381590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.
    Moss TJ; Qi Y; Xi L; Peng B; Kim TB; Ezzedine NE; Mosqueda ME; Guo CC; Czerniak BA; Ittmann M; Wheeler DA; Lerner SP; Matin SF
    Eur Urol; 2017 Oct; 72(4):641-649. PubMed ID: 28601352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ureteroscopic management of upper tract urothelial carcinoma (UTUC) in patients with Lynch Syndrome (hereditary nonpolyposis colorectal cancer syndrome).
    Hubosky SG; Boman BM; Charles S; Bibbo M; Bagley DH
    BJU Int; 2013 Oct; 112(6):813-9. PubMed ID: 23452166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Universal Lynch Syndrome Screening Should be Performed in All Upper Tract Urothelial Carcinomas.
    Ju JY; Mills AM; Mahadevan MS; Fan J; Culp SH; Thomas MH; Cathro HP
    Am J Surg Pathol; 2018 Nov; 42(11):1549-1555. PubMed ID: 30148743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in genomic profile of high-grade urothelial carcinoma according to tumor location.
    Park CK; Cho NH
    Urol Oncol; 2022 Mar; 40(3):109.e1-109.e9. PubMed ID: 34663543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites.
    Nassar AH; Umeton R; Kim J; Lundgren K; Harshman L; Van Allen EM; Preston M; Dong F; Bellmunt J; Mouw KW; Choueiri TK; Sonpavde G; Kwiatkowski DJ
    Clin Cancer Res; 2019 Apr; 25(8):2458-2470. PubMed ID: 30593515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptomic Profiling of Upper Tract Urothelial Carcinoma: Bladder Cancer Consensus Classification Relevance, Molecular Heterogeneity, and Differential Immune Signatures.
    Fontugne J; Xylinas E; Krucker C; Dixon V; Groeneveld CS; Pinar U; Califano G; Bucau M; Verine J; Desgrandchamps F; Hermieu JF; Radvanyi F; Allory Y; Masson-Lecomte A
    Mod Pathol; 2023 Nov; 36(11):100300. PubMed ID: 37558130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results.
    Pal SK; Bajorin D; Dizman N; Hoffman-Censits J; Quinn DI; Petrylak DP; Galsky MD; Vaishampayan U; De Giorgi U; Gupta S; Burris HA; Soifer HS; Li G; Wang H; Dambkowski CL; Moran S; Daneshmand S; Rosenberg JE
    Cancer; 2020 Jun; 126(11):2597-2606. PubMed ID: 32208524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Carcinogenic pathways and natural history of upper tract urothelial carcinomas: state-of-the-art review for the yearly scientific report of the French National Association of Urology].
    Seisen T; Cancel-Tassin G; Colin P; Cussenot O; Rouprêt M
    Prog Urol; 2014 Nov; 24(15):943-53. PubMed ID: 25158326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.